IRX
Inhalerx Ltd
Director Trades
| Date | Director | Value |
|---|
Company News
Weekly wrap: RBA was right on rates and it cost us a record
There will be no letup in the political attacks against it but the share market has finally conceded that the Reserve Bank was absolutely right not to cut interest rates this year. With Australian employment growth now hitting a 16-month high and workforce participation at a record, with inflation still sticky, the Reserve Bank’s caution […]
InhaleRx procures $38.5m in funding from Clendon Biotech to progress inhaled therapies
Healthcare company InhaleRx (ASX: IRX) has entered into an agreement with Melbourne-headquartered Clendon Biotech Capital to provide up to $38.5 million in funding to cover costs associated with developing it’s unique inhaled therapies. Clendon’s funding will fully cover the costs – including those from associated non-clinical work and trial drug manufacturing – for the IRX-211 […]
InhaleRx submits ethics application for IRX616a to treat panic disorder
Australian healthcare company InhaleRx (ASX: IRX) has submitted an ethics application for a Phase 2a clinical trial investigating the safety and efficacy of lead candidate IRX616a in patients with panic disorder. The application was submitted to Bellberry Human Research Ethics Committee last week and is based on a proof-of-concept trial to be carried out at […]
InhaleRx completes second cohort of IRX211 trial for pain management
Australian healthcare company InhaleRx (ASX: IRX) has completed the second of four cohorts in a Phase 1 clinical trial investigating the safety and pharmacokinetics of lead cannabinoid drug delivery system IRX211. The company has now recruited and dosed 16 participants across the first and second cohorts of the trial, which is focused on potential treatments […]
InhaleRx advances clinical trials of CBD drugs for treatment of acute pain and panic disorder
Australian healthcare company InhaleRx (ASX: IRX) has advanced the activation of a Phase 1 trial of cannabinoid (CBD)-derived inhaled drug IRX211 for the treatment of acute pain and the preparation of ethics application for a Phase 2 trial of CBD formulation IRX616a for panic disorder. The Phase 1 trial is considered a critical cornerstone for […]
InhaleRx completes first cohort of phase 1 clinical trial for pain management
Melbourne-based healthcare company InhaleRx (ASX: IRX) continues to confirm the potential of its inhaled medication pain medicine systems with the completion of an initial set of trials. The company has confirmed that phase 1 clinical trials have been successfully undertaken with the first of four cohorts passing through its investigation of the safety and pharmacokinetics […]
InhaleRx takes big first step to enter $210 billion pain management market
Melbourne-headquartered pain management treatment developer InhaleRx (ASX: IRX) has moved further along the path towards product commercialisation of its IRX211 drug with the maiden dosing of a patient in new trials in Melbourne. The global chronic pain market was valued at US$69.1 billion (A$103.6 billion) in 2021 and the worldwide chronic pain market size is […]
InhaleRx locks-in ethics approval for phase 1 trial of novel drug IRX211 in treating CRPS
InhaleRx (ASX: IRX) is a step closer to kicking-off a phase 1 clinical trial of its novel inhaled cannabinoid formulation IRX211 for complex regional pain syndrome (CRPS) after locking in ethics approval. Alfred Health Human Ethics Committee (HREC) approved the trial, which will investigate the safety and pharmacokinetics of IRX211 at Nucleus Network in Melbourne. […]
InhaleRx reveals ‘important progress’ in inhaled cannabinoid drugs for CRPS and panic disorder
Australian biotech InhaleRx (ASX: IRX) has made “important progress” in the development of its novel inhaled drug formulations for complex regional pain syndrome (CRPS) and panic disorder. CRPS is described as a chronic pain syndrome with paroxysmal breakthrough pain, which needs immediate pain relief to manage. Similarly, panic disorder, which causes sudden overwhelming anxiety symptoms […]
InhaleRx is gearing up for a clinical trial in treating panic disorder next year
InhaleRx (ASX: IRX) is a step closer to clinical trials after appointing Ingenu as the contract research organisation (CRO) for the studies. The company is developing unique medicinal cannabinoid drug-device products to meet unmet medical needs in treating complex regional pain syndrome and panic disorder. InhaleRx chairman Sean Williams said Ingenu had been selected following […]
